Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycobacterium w for COVID-19 Prevention
NCT04353518Phase 3Unknown
- Sponsor
- Cadila Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of MYCIDAC-C in coronavirus disease 2019 (COVID-19), sponsored by Cadila Pharmaceuticals. Status: unknown.
02
Drugs
MYCIDAC-C
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04353518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353518.